Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.63 |
| ▸ | F2R | P25116 | 7/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7500212 | 0.97 | ITGB3 (0.60) | ITGB3ITGA2BF2RHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7500055 | 0.89 | ITGB3 (0.60) | ITGB3ITGA2BF2RHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7500524 | 0.88 | ITGB3 (0.59) | ITGB3ITGA2BF2RHTTSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL7747734 | 0.86 | ITGB3 (0.58) | ITGB3ITGA2BF2R | |
| Trifluoroacetic Acid SCHEMBL7500215 | 0.84 | ITGB3 (0.54) | ITGB3ITGA2BF2R | |
| SCHEMBL7504164 | 0.84 | ITGB3 (0.74) | ITGB3ITGA2BF2RHTTSMN1; SMN2 | |
| SCHEMBL7505296 | 0.84 | ITGB3 (0.62) | ITGB3ITGA2BF2RHTTSMN1; SMN2 | |
| SCHEMBL7446986 | 0.83 | ITGB3 (0.73) | ITGB3ITGA2BF2RHTTSMN1; SMN2 | |
| SCHEMBL7500565 | 0.83 | ITGB3 (0.72) | ITGB3ITGA2BF2RHTTSMN1; SMN2 | |
| SCHEMBL7508377 | 0.81 | ITGB3 (0.65) | ITGB3ITGA2BF2RHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0669912-B1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | ITGB3 52/4885ITGA2B 14/4885F2R 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.